US Stock MarketDetailed Quotes

AVRO Avrobio

Watchlist
  • 1.2300
  • +0.0100+0.82%
Close May 2 16:00 ET
  • 1.2300
  • 0.00000.00%
Post 19:06 ET
55.20MMarket Cap4.56P/E (TTM)

About Avrobio Company

Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firm's clinical-stage programs include Fabry, Gaucher Type 1, Hunter syndrome Gaucher Type 3, Pompe, and Cystinosis. The company was founded by Geoff Mackay, Kim Warren, Christopher Mason, and Jeffrey Medin in 2015 and is headquartered in Cambridge, MA.

Company Profile

SymbolAVRO
Company NameAvrobio
Listing DateJun 21, 2018
Issue Price19.00
Founded2015
CEOMr. Erik John Ostrowski
MarketNASDAQ
Employees13
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address100 Technology Square,6th floor
CityCambridge
ProvinceMassachusetts
CountryUnited States of America
Zip Code02139
Phone1-617-914-8420
Websitehttp://www.avrobio.com

Company Executives

  • Name
  • Position
  • Salary
  • Erik John Ostrowski
  • President, Interim Chief Executive Officer, Treasurer, Chief Financial Officer and Principal Accounting Officer
  • 1.35M
  • Dr. Azadeh Golipour, PhD
  • Chief Technology Officer
  • 1.03M
  • Steven N. Avruch
  • Chief Legal Officer and Secretary
  • --
  • Essra Ridha
  • Chief Medical Officer
  • --
  • Dr. Bruce Booth, D.Phil.
  • Chairman of the Board
  • 110.33K
  • Dr. Gail M. Farfel, PhD
  • Director
  • 72.83K
  • Dr. Philip J. Vickers, PhD
  • Independent Director
  • 85.33K
  • Dr. Annalisa Mary Jenkins
  • Independent Director
  • 88.33K
  • Phillip B. Donenberg
  • Independent Director
  • 84.33K
  • Ian T. Clark
  • Independent Director
  • 75.33K
  • Dr. Christopher Paige, PhD
  • Independent Director
  • 84.33K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg